RN-1201

N/A

Report date: 2025/08/06 20:01:14

Base Information

Drug NameRN-1201

Drug Alias NameRN1201RN-1201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsThrombocytopenia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe First Affiliated Hospital Of Soochow University

China Registration ClassN/A

Develop Information

Active CompaniesAlloRunning Therapeutics Co Ltd The First Affiliated Hospital Of Soochow University

Inactive CompaniesN/A

Active IndicationsThrombocytopenia

Inactive IndicationsN/A

Other Information

ATC CodeN/A